武漢佰樂博代理：Research Grade Sabatolimab  

貨號：DHJ28402

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75240.html

產(chǎn)品購買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Sabatolimab (MBG453)是一種高親和力的人源化IgG4 (S228P)抗體，靶向TIM-3，一種調(diào)節(jié)適應(yīng)性和先天免疫反應(yīng)的抑制性受體。Sabatolimab是一種潛在的免疫抑制活性分子，可以靶向免疫細(xì)胞和骨髓細(xì)胞上的TIM-3。

通用名：Sabatolimab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：MBG-453

靶點(diǎn);物種：Human CD366/HAVCR2/TIM-3

種類：Humanized

受體鑒定：IgG4-kappa

CAS: 2252262-24-9

存儲條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn)：

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. PMID: 33883177

Advances in myelodysplastic syndrome. PMID: 34474438

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. PMID: 36196369

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. PMID: 35883692

Updates on the Management of Acute Myeloid Leukemia. PMID: 36230677

Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors. PMID: 37186155

New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes. PMID: 35886899

STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. PMID: 37083373

TIM-3: a tumor-associated antigen beyond checkpoint inhibition? PMID: 36406467

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. PMID: 36819977

[Management of AML in the elderly]. PMID: 36870810

New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. PMID: 35218498

EXABS-120-MDS Treatment of Higher Risk MDS. PMID: 36163758

EXABS-140-MDS Immune Therapy Approaches in MDS. PMID: 36164227

Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon? PMID: 33762100

Advances in myelodysplastic syndromes: promising novel agents and combination strategies. PMID: 36620919

Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. PMID: 36215988

Biological therapy in elderly patients with acute myeloid leukemia. PMID: 36715330

Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter? PMID: 34944985